Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japan Ethical Drug Sales Drop 9.6% in September: Crecon
November 10, 2020
- Ono Launches Japan PIII Study for Foipan for COVID-19
November 10, 2020
- Big 4 Wholesalers Suffer 80% Drop in Operating Profit on COVID, Discount, Price Battle: 1H 2020
November 9, 2020
- Kyorin Jettisons Gene Therapy Ad-SGE-REIC after Bleak PII Results
November 9, 2020
- Expert Panel Delivers Harsh Verdict on Aducanumab, FDA Decision Due by March 7
November 9, 2020
- Xtandi Approved in China for Non-Metastatic CRPC
November 9, 2020
- Keytruda Top Selling Drug for 3 Months on End: Encise October Data
November 9, 2020
- 1st Half Sales of 7 Major Japan Drug Makers Skid 1.9% on Price Cuts, COVID-19; Core Products Brisk
November 6, 2020
- Before Aducanumab AdCom, Eisai CEO Voices Hopes for Potential 1st Alzheimer’s Drug in 17 Years
November 6, 2020
- Eisai Racks Up 5.9% Sales Increase in April-September on Lenvima Growth, Despite Price Cuts, COVID-19
November 6, 2020
- In a Digital Push, Takeda Encouraging Sales Reps to Gain IT Qualification: Japan Chief
November 5, 2020
- Mitsubishi Tanabe Incurs 60 Billion-Plus Yen Operating Loss in 1st Half as Parkinson’s Program Lags
November 5, 2020
- Prescriptions Down at 41% of Medical Institutions due to COVID-19: Survey
November 5, 2020
- AstraZeneca Approached Us for Manufacturing of Coronavirus Vaccine Solution: JCR Exec
November 5, 2020
- Sosei, Aditum Bio Form New Firm to Develop Neurological Disease Drugs
November 4, 2020
- Astellas Now Aims at Peak Sales of 300-400 Billion Yen for Padcev with New Indications
November 4, 2020
- Shionogi/Tetra’s Cognitive Disorder Med Delivers Positive PII Data
November 4, 2020
- JCR Can Strike Global Licensing Deal for Lysosomal Therapies at Least by March-End: Chief
November 4, 2020
- Kyowa Kirin’s Overseas Sales Ratio Nears 50%, Driven by Crysvita in Europe, US: January-September
November 4, 2020
- Daiichi Sankyo Promoting Home Use of Inavir to Reduce COVID-19 Risk at Medical Institutions
November 4, 2020
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…